Promedior is developing a pipeline of drug candidates that act on the
fibrotic disease process by targeting the specific monocyte-derived cell
populations that play key roles in fibrotic, inflammatory and autoimmune
diseases. The company’s most advanced product development programs, including
its lead product PRM-151, are based on Promedior’s proprietary discoveries
related to SAP, and this protein’s unique roles in regulating the response of
the innate immune system to injury.
Promedior intends to initially pursue ophthalmic indications associated
with aberrant tissue remodeling, followed by clinical studies for chronic
Pulmonary and Renal indications using systemic administration.
PRM-151
Promedior’s lead product, PRM-151, is a recombinant form of human Serum
Amyloid P (rhSAP) with broadly active anti-fibrotic activity. PRM-151 has
demonstrated an outstanding safety profile and robust preclinical efficacy in
multiple models of fibrotic disease and tissue remodeling, including Idiopathic
Pulmonary Fibrosis and Asthma, as well as ophthalmic, kidney, heart, and liver
disease. Promedior initiated a Phase 1 clinical trial of PRM-151 in July
2009. The Phase 1 dose escalation study is designed to evaluate the
safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of
ascending single intravenous doses of PRM-151.